COVID‐19 in lung transplant recipients: A single center case series from New York City
There are limited data describing COVID‐19 in lung transplant recipients. We performed a single center, retrospective case series study of lung transplant patients followed by the Columbia Lung Transplant program who tested positive for SARS‐CoV‐2 between March 19 and May 19, 2020. Thirty‐two lung t...
Gespeichert in:
| Veröffentlicht in: | American journal of transplantation 2020-11, Vol.20 (11), p.3072-3080 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3080 |
|---|---|
| container_issue | 11 |
| container_start_page | 3072 |
| container_title | American journal of transplantation |
| container_volume | 20 |
| creator | Aversa, Meghan Benvenuto, Luke Anderson, Michaela Shah, Lori Robbins, Hilary Pereira, Marcus Scheffert, Jenna Carroll, Maggie Hum, Jamie Nolan, Margaret Reilly, Genevieve Lemaitre, Philippe Stanifer, Bryan P. D’Ovidio, Frank Sonett, Joshua Arcasoy, Selim |
| description | There are limited data describing COVID‐19 in lung transplant recipients. We performed a single center, retrospective case series study of lung transplant patients followed by the Columbia Lung Transplant program who tested positive for SARS‐CoV‐2 between March 19 and May 19, 2020. Thirty‐two lung transplant patients developed mild (16%), moderate (44%), or severe (41%) COVID‐19. The median age of patients was 65 years, and the median time from lung transplant was 5.6 years. Symptoms included cough (66%), dyspnea (50%), fever (47%), and gastrointestinal upset (44%). Patients received hydroxychloroquine (84%), azithromycin (75%), augmented steroids (44%), tocilizumab (19%), and remdesivir (9%). Eleven patients (34%) died at a median time of 14 days from admission. Complications during admission included: acute kidney injury (63%), transaminitis (31%), shock (31%), acute respiratory distress syndrome (25%), neurological events (25%), arrhythmias (22%), and venous thromboembolism (9%). Compared to patients with moderate COVID‐19, patients with severe COVID‐19 had higher peak white blood cell counts (15.8 vs 7 × 103/uL, P = .019), C‐reactive protein (198 vs. 107 mg/L, P = .010) and D‐dimer (8.6 vs. 2.1 ug/mL, P = .004) levels, and lower nadir lymphocyte counts (0.09 vs. 0.4 × 103/uL, P = .006). COVID‐19 is associated with severe illness and a high mortality rate in lung transplant recipients.
The authors describe the significant morbidity and mortality associated with COVID‐19 among lung transplant recipients. |
| doi_str_mv | 10.1111/ajt.16241 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7436464</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2455935300</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4711-77f5eb08a74aed6fd2d5d3815bedfdfbdea38eb033a941d53846c955f7fa17453</originalsourceid><addsrcrecordid>eNp1kcFuEzEURS0EIqGw6A9UltjAIo3f2B7PsKgUBWiDKroJCFaWM35OHSYzwZ6hyo5P4Bv7JXVIiQoS3thPPjq6T5eQY2CnkM7YrLpTyDMBj8gQcsZGOQj--PDmckCexbhiDFRWZE_JgGdFARzkkHyZXn2evb39-QtK6hta982SdsE0cVObpqMBK7_x2HTxDZ3Q6JtljbRKMwZamYg0YvAYqQvtmn7EG_q1Dd_o1Hfb5-SJM3XEF_f3Efn0_t18ejG6vDqfTSeXo0oogJFSTuKCFUYJgzZ3NrPS8gLkAq2zbmHR8CIBnJtSgJW8EHlVSumUM6CE5EfkbO_d9Is12l22YGq9CX5twla3xuu_fxp_rZftD60Ez0UukuDVvSC033uMnV77WGGd9se2jzoTvCxVrjJI6Mt_0FXbhyatlygpSy45Y4l6vaeq0MYY0B3CANO7vnTqS__uK7EnD9MfyD8FJWC8B258jdv_m_Tkw3yvvAPteJ_-</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2455935300</pqid></control><display><type>article</type><title>COVID‐19 in lung transplant recipients: A single center case series from New York City</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Aversa, Meghan ; Benvenuto, Luke ; Anderson, Michaela ; Shah, Lori ; Robbins, Hilary ; Pereira, Marcus ; Scheffert, Jenna ; Carroll, Maggie ; Hum, Jamie ; Nolan, Margaret ; Reilly, Genevieve ; Lemaitre, Philippe ; Stanifer, Bryan P. ; D’Ovidio, Frank ; Sonett, Joshua ; Arcasoy, Selim</creator><creatorcontrib>Aversa, Meghan ; Benvenuto, Luke ; Anderson, Michaela ; Shah, Lori ; Robbins, Hilary ; Pereira, Marcus ; Scheffert, Jenna ; Carroll, Maggie ; Hum, Jamie ; Nolan, Margaret ; Reilly, Genevieve ; Lemaitre, Philippe ; Stanifer, Bryan P. ; D’Ovidio, Frank ; Sonett, Joshua ; Arcasoy, Selim ; From the Columbia University Lung Transplant Program</creatorcontrib><description>There are limited data describing COVID‐19 in lung transplant recipients. We performed a single center, retrospective case series study of lung transplant patients followed by the Columbia Lung Transplant program who tested positive for SARS‐CoV‐2 between March 19 and May 19, 2020. Thirty‐two lung transplant patients developed mild (16%), moderate (44%), or severe (41%) COVID‐19. The median age of patients was 65 years, and the median time from lung transplant was 5.6 years. Symptoms included cough (66%), dyspnea (50%), fever (47%), and gastrointestinal upset (44%). Patients received hydroxychloroquine (84%), azithromycin (75%), augmented steroids (44%), tocilizumab (19%), and remdesivir (9%). Eleven patients (34%) died at a median time of 14 days from admission. Complications during admission included: acute kidney injury (63%), transaminitis (31%), shock (31%), acute respiratory distress syndrome (25%), neurological events (25%), arrhythmias (22%), and venous thromboembolism (9%). Compared to patients with moderate COVID‐19, patients with severe COVID‐19 had higher peak white blood cell counts (15.8 vs 7 × 103/uL, P = .019), C‐reactive protein (198 vs. 107 mg/L, P = .010) and D‐dimer (8.6 vs. 2.1 ug/mL, P = .004) levels, and lower nadir lymphocyte counts (0.09 vs. 0.4 × 103/uL, P = .006). COVID‐19 is associated with severe illness and a high mortality rate in lung transplant recipients.
The authors describe the significant morbidity and mortality associated with COVID‐19 among lung transplant recipients.</description><identifier>ISSN: 1600-6135</identifier><identifier>EISSN: 1600-6143</identifier><identifier>DOI: 10.1111/ajt.16241</identifier><identifier>PMID: 32881315</identifier><language>eng</language><publisher>United States: Elsevier Limited</publisher><subject>Adult ; Aged ; Antibiotics ; Antibodies, Monoclonal, Humanized - therapeutic use ; Antiviral Agents - therapeutic use ; Antiviral drugs ; Azithromycin ; Cough ; COVID-19 ; COVID-19 - epidemiology ; COVID-19 Drug Treatment ; Dyspnea ; Female ; Fever ; Graft Rejection - epidemiology ; Graft Rejection - prevention & control ; Humans ; Hydroxychloroquine ; Immunosuppression Therapy - methods ; Incidence ; Lung Transplantation ; Lung transplants ; Lymphocytes ; Male ; Middle Aged ; Monoclonal antibodies ; New York City - epidemiology ; Original ; ORIGINAL ARTICLES ; Pandemics ; Respiration ; Respiratory distress syndrome ; Retrospective Studies ; SARS-CoV-2 ; Severe acute respiratory syndrome coronavirus 2 ; Steroid hormones ; Survival Rate - trends ; Thromboembolism ; Transplant Recipients</subject><ispartof>American journal of transplantation, 2020-11, Vol.20 (11), p.3072-3080</ispartof><rights>2020 The American Society of Transplantation and the American Society of Transplant Surgeons</rights><rights>2020 The American Society of Transplantation and the American Society of Transplant Surgeons.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4711-77f5eb08a74aed6fd2d5d3815bedfdfbdea38eb033a941d53846c955f7fa17453</citedby><cites>FETCH-LOGICAL-c4711-77f5eb08a74aed6fd2d5d3815bedfdfbdea38eb033a941d53846c955f7fa17453</cites><orcidid>0000-0002-9214-9122 ; 0000-0001-8005-8074 ; 0000-0003-1678-2345 ; 0000-0002-7361-0024 ; 0000-0003-2477-6818 ; 0000-0001-9274-7643</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fajt.16241$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fajt.16241$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32881315$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Aversa, Meghan</creatorcontrib><creatorcontrib>Benvenuto, Luke</creatorcontrib><creatorcontrib>Anderson, Michaela</creatorcontrib><creatorcontrib>Shah, Lori</creatorcontrib><creatorcontrib>Robbins, Hilary</creatorcontrib><creatorcontrib>Pereira, Marcus</creatorcontrib><creatorcontrib>Scheffert, Jenna</creatorcontrib><creatorcontrib>Carroll, Maggie</creatorcontrib><creatorcontrib>Hum, Jamie</creatorcontrib><creatorcontrib>Nolan, Margaret</creatorcontrib><creatorcontrib>Reilly, Genevieve</creatorcontrib><creatorcontrib>Lemaitre, Philippe</creatorcontrib><creatorcontrib>Stanifer, Bryan P.</creatorcontrib><creatorcontrib>D’Ovidio, Frank</creatorcontrib><creatorcontrib>Sonett, Joshua</creatorcontrib><creatorcontrib>Arcasoy, Selim</creatorcontrib><creatorcontrib>From the Columbia University Lung Transplant Program</creatorcontrib><title>COVID‐19 in lung transplant recipients: A single center case series from New York City</title><title>American journal of transplantation</title><addtitle>Am J Transplant</addtitle><description>There are limited data describing COVID‐19 in lung transplant recipients. We performed a single center, retrospective case series study of lung transplant patients followed by the Columbia Lung Transplant program who tested positive for SARS‐CoV‐2 between March 19 and May 19, 2020. Thirty‐two lung transplant patients developed mild (16%), moderate (44%), or severe (41%) COVID‐19. The median age of patients was 65 years, and the median time from lung transplant was 5.6 years. Symptoms included cough (66%), dyspnea (50%), fever (47%), and gastrointestinal upset (44%). Patients received hydroxychloroquine (84%), azithromycin (75%), augmented steroids (44%), tocilizumab (19%), and remdesivir (9%). Eleven patients (34%) died at a median time of 14 days from admission. Complications during admission included: acute kidney injury (63%), transaminitis (31%), shock (31%), acute respiratory distress syndrome (25%), neurological events (25%), arrhythmias (22%), and venous thromboembolism (9%). Compared to patients with moderate COVID‐19, patients with severe COVID‐19 had higher peak white blood cell counts (15.8 vs 7 × 103/uL, P = .019), C‐reactive protein (198 vs. 107 mg/L, P = .010) and D‐dimer (8.6 vs. 2.1 ug/mL, P = .004) levels, and lower nadir lymphocyte counts (0.09 vs. 0.4 × 103/uL, P = .006). COVID‐19 is associated with severe illness and a high mortality rate in lung transplant recipients.
The authors describe the significant morbidity and mortality associated with COVID‐19 among lung transplant recipients.</description><subject>Adult</subject><subject>Aged</subject><subject>Antibiotics</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Antiviral drugs</subject><subject>Azithromycin</subject><subject>Cough</subject><subject>COVID-19</subject><subject>COVID-19 - epidemiology</subject><subject>COVID-19 Drug Treatment</subject><subject>Dyspnea</subject><subject>Female</subject><subject>Fever</subject><subject>Graft Rejection - epidemiology</subject><subject>Graft Rejection - prevention & control</subject><subject>Humans</subject><subject>Hydroxychloroquine</subject><subject>Immunosuppression Therapy - methods</subject><subject>Incidence</subject><subject>Lung Transplantation</subject><subject>Lung transplants</subject><subject>Lymphocytes</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>New York City - epidemiology</subject><subject>Original</subject><subject>ORIGINAL ARTICLES</subject><subject>Pandemics</subject><subject>Respiration</subject><subject>Respiratory distress syndrome</subject><subject>Retrospective Studies</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Steroid hormones</subject><subject>Survival Rate - trends</subject><subject>Thromboembolism</subject><subject>Transplant Recipients</subject><issn>1600-6135</issn><issn>1600-6143</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kcFuEzEURS0EIqGw6A9UltjAIo3f2B7PsKgUBWiDKroJCFaWM35OHSYzwZ6hyo5P4Bv7JXVIiQoS3thPPjq6T5eQY2CnkM7YrLpTyDMBj8gQcsZGOQj--PDmckCexbhiDFRWZE_JgGdFARzkkHyZXn2evb39-QtK6hta982SdsE0cVObpqMBK7_x2HTxDZ3Q6JtljbRKMwZamYg0YvAYqQvtmn7EG_q1Dd_o1Hfb5-SJM3XEF_f3Efn0_t18ejG6vDqfTSeXo0oogJFSTuKCFUYJgzZ3NrPS8gLkAq2zbmHR8CIBnJtSgJW8EHlVSumUM6CE5EfkbO_d9Is12l22YGq9CX5twla3xuu_fxp_rZftD60Ez0UukuDVvSC033uMnV77WGGd9se2jzoTvCxVrjJI6Mt_0FXbhyatlygpSy45Y4l6vaeq0MYY0B3CANO7vnTqS__uK7EnD9MfyD8FJWC8B258jdv_m_Tkw3yvvAPteJ_-</recordid><startdate>202011</startdate><enddate>202011</enddate><creator>Aversa, Meghan</creator><creator>Benvenuto, Luke</creator><creator>Anderson, Michaela</creator><creator>Shah, Lori</creator><creator>Robbins, Hilary</creator><creator>Pereira, Marcus</creator><creator>Scheffert, Jenna</creator><creator>Carroll, Maggie</creator><creator>Hum, Jamie</creator><creator>Nolan, Margaret</creator><creator>Reilly, Genevieve</creator><creator>Lemaitre, Philippe</creator><creator>Stanifer, Bryan P.</creator><creator>D’Ovidio, Frank</creator><creator>Sonett, Joshua</creator><creator>Arcasoy, Selim</creator><general>Elsevier Limited</general><general>John Wiley and Sons Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-9214-9122</orcidid><orcidid>https://orcid.org/0000-0001-8005-8074</orcidid><orcidid>https://orcid.org/0000-0003-1678-2345</orcidid><orcidid>https://orcid.org/0000-0002-7361-0024</orcidid><orcidid>https://orcid.org/0000-0003-2477-6818</orcidid><orcidid>https://orcid.org/0000-0001-9274-7643</orcidid></search><sort><creationdate>202011</creationdate><title>COVID‐19 in lung transplant recipients: A single center case series from New York City</title><author>Aversa, Meghan ; Benvenuto, Luke ; Anderson, Michaela ; Shah, Lori ; Robbins, Hilary ; Pereira, Marcus ; Scheffert, Jenna ; Carroll, Maggie ; Hum, Jamie ; Nolan, Margaret ; Reilly, Genevieve ; Lemaitre, Philippe ; Stanifer, Bryan P. ; D’Ovidio, Frank ; Sonett, Joshua ; Arcasoy, Selim</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4711-77f5eb08a74aed6fd2d5d3815bedfdfbdea38eb033a941d53846c955f7fa17453</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antibiotics</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Antiviral drugs</topic><topic>Azithromycin</topic><topic>Cough</topic><topic>COVID-19</topic><topic>COVID-19 - epidemiology</topic><topic>COVID-19 Drug Treatment</topic><topic>Dyspnea</topic><topic>Female</topic><topic>Fever</topic><topic>Graft Rejection - epidemiology</topic><topic>Graft Rejection - prevention & control</topic><topic>Humans</topic><topic>Hydroxychloroquine</topic><topic>Immunosuppression Therapy - methods</topic><topic>Incidence</topic><topic>Lung Transplantation</topic><topic>Lung transplants</topic><topic>Lymphocytes</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>New York City - epidemiology</topic><topic>Original</topic><topic>ORIGINAL ARTICLES</topic><topic>Pandemics</topic><topic>Respiration</topic><topic>Respiratory distress syndrome</topic><topic>Retrospective Studies</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Steroid hormones</topic><topic>Survival Rate - trends</topic><topic>Thromboembolism</topic><topic>Transplant Recipients</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aversa, Meghan</creatorcontrib><creatorcontrib>Benvenuto, Luke</creatorcontrib><creatorcontrib>Anderson, Michaela</creatorcontrib><creatorcontrib>Shah, Lori</creatorcontrib><creatorcontrib>Robbins, Hilary</creatorcontrib><creatorcontrib>Pereira, Marcus</creatorcontrib><creatorcontrib>Scheffert, Jenna</creatorcontrib><creatorcontrib>Carroll, Maggie</creatorcontrib><creatorcontrib>Hum, Jamie</creatorcontrib><creatorcontrib>Nolan, Margaret</creatorcontrib><creatorcontrib>Reilly, Genevieve</creatorcontrib><creatorcontrib>Lemaitre, Philippe</creatorcontrib><creatorcontrib>Stanifer, Bryan P.</creatorcontrib><creatorcontrib>D’Ovidio, Frank</creatorcontrib><creatorcontrib>Sonett, Joshua</creatorcontrib><creatorcontrib>Arcasoy, Selim</creatorcontrib><creatorcontrib>From the Columbia University Lung Transplant Program</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>American journal of transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aversa, Meghan</au><au>Benvenuto, Luke</au><au>Anderson, Michaela</au><au>Shah, Lori</au><au>Robbins, Hilary</au><au>Pereira, Marcus</au><au>Scheffert, Jenna</au><au>Carroll, Maggie</au><au>Hum, Jamie</au><au>Nolan, Margaret</au><au>Reilly, Genevieve</au><au>Lemaitre, Philippe</au><au>Stanifer, Bryan P.</au><au>D’Ovidio, Frank</au><au>Sonett, Joshua</au><au>Arcasoy, Selim</au><aucorp>From the Columbia University Lung Transplant Program</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>COVID‐19 in lung transplant recipients: A single center case series from New York City</atitle><jtitle>American journal of transplantation</jtitle><addtitle>Am J Transplant</addtitle><date>2020-11</date><risdate>2020</risdate><volume>20</volume><issue>11</issue><spage>3072</spage><epage>3080</epage><pages>3072-3080</pages><issn>1600-6135</issn><eissn>1600-6143</eissn><abstract>There are limited data describing COVID‐19 in lung transplant recipients. We performed a single center, retrospective case series study of lung transplant patients followed by the Columbia Lung Transplant program who tested positive for SARS‐CoV‐2 between March 19 and May 19, 2020. Thirty‐two lung transplant patients developed mild (16%), moderate (44%), or severe (41%) COVID‐19. The median age of patients was 65 years, and the median time from lung transplant was 5.6 years. Symptoms included cough (66%), dyspnea (50%), fever (47%), and gastrointestinal upset (44%). Patients received hydroxychloroquine (84%), azithromycin (75%), augmented steroids (44%), tocilizumab (19%), and remdesivir (9%). Eleven patients (34%) died at a median time of 14 days from admission. Complications during admission included: acute kidney injury (63%), transaminitis (31%), shock (31%), acute respiratory distress syndrome (25%), neurological events (25%), arrhythmias (22%), and venous thromboembolism (9%). Compared to patients with moderate COVID‐19, patients with severe COVID‐19 had higher peak white blood cell counts (15.8 vs 7 × 103/uL, P = .019), C‐reactive protein (198 vs. 107 mg/L, P = .010) and D‐dimer (8.6 vs. 2.1 ug/mL, P = .004) levels, and lower nadir lymphocyte counts (0.09 vs. 0.4 × 103/uL, P = .006). COVID‐19 is associated with severe illness and a high mortality rate in lung transplant recipients.
The authors describe the significant morbidity and mortality associated with COVID‐19 among lung transplant recipients.</abstract><cop>United States</cop><pub>Elsevier Limited</pub><pmid>32881315</pmid><doi>10.1111/ajt.16241</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-9214-9122</orcidid><orcidid>https://orcid.org/0000-0001-8005-8074</orcidid><orcidid>https://orcid.org/0000-0003-1678-2345</orcidid><orcidid>https://orcid.org/0000-0002-7361-0024</orcidid><orcidid>https://orcid.org/0000-0003-2477-6818</orcidid><orcidid>https://orcid.org/0000-0001-9274-7643</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1600-6135 |
| ispartof | American journal of transplantation, 2020-11, Vol.20 (11), p.3072-3080 |
| issn | 1600-6135 1600-6143 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7436464 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adult Aged Antibiotics Antibodies, Monoclonal, Humanized - therapeutic use Antiviral Agents - therapeutic use Antiviral drugs Azithromycin Cough COVID-19 COVID-19 - epidemiology COVID-19 Drug Treatment Dyspnea Female Fever Graft Rejection - epidemiology Graft Rejection - prevention & control Humans Hydroxychloroquine Immunosuppression Therapy - methods Incidence Lung Transplantation Lung transplants Lymphocytes Male Middle Aged Monoclonal antibodies New York City - epidemiology Original ORIGINAL ARTICLES Pandemics Respiration Respiratory distress syndrome Retrospective Studies SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Steroid hormones Survival Rate - trends Thromboembolism Transplant Recipients |
| title | COVID‐19 in lung transplant recipients: A single center case series from New York City |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T12%3A56%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=COVID%E2%80%9019%20in%20lung%20transplant%20recipients:%20A%20single%20center%20case%20series%20from%20New%20York%20City&rft.jtitle=American%20journal%20of%20transplantation&rft.au=Aversa,%20Meghan&rft.aucorp=From%20the%20Columbia%20University%20Lung%20Transplant%20Program&rft.date=2020-11&rft.volume=20&rft.issue=11&rft.spage=3072&rft.epage=3080&rft.pages=3072-3080&rft.issn=1600-6135&rft.eissn=1600-6143&rft_id=info:doi/10.1111/ajt.16241&rft_dat=%3Cproquest_pubme%3E2455935300%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2455935300&rft_id=info:pmid/32881315&rfr_iscdi=true |